Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/Hepatitis C Virus (HCV) Seronegative Volunteers

Trial Profile

Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/Hepatitis C Virus (HCV) Seronegative Volunteers

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Dolutegravir (Primary) ; Simeprevir (Primary)
  • Indications Hepatitis C; HIV infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 04 Oct 2017 Results published in the Journal of Antimicrobial Chemotherapy.
    • 21 Nov 2016 Status changed from recruiting to completed.
    • 03 Feb 2016 Planned End Date changed from 1 Mar 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top